Bristol-Myers Squibb Co (NYSE: BMY) kicked off on Monday, up 1.24% from the previous trading day, before settling in for the closing price of $50.71. Over the past 52 weeks, BMY has traded in a range of $39.35-$63.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 15.21% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 486.77%. With a float of $2.03 billion, this company’s outstanding shares have now reached $2.03 billion.
In an organization with 34100 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 66.66%, operating margin of 18.92%, and the pretax margin is -17.35%.
Bristol-Myers Squibb Co (BMY) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – General Industry. The insider ownership of Bristol-Myers Squibb Co is 0.08%, while institutional ownership is 79.76%. The most recent insider transaction that took place on Feb 20 ’25, was worth 110,096. In this transaction Chief Executive Officer of this company bought 2,000 shares at a rate of $55.05, taking the stock ownership to the 104,626 shares. Before that another transaction happened on Feb 14 ’25, when Company’s EVP,Chief Med.Offr.,Drug Dev. bought 1,823 for $54.84, making the entire transaction worth $100,000. This insider now owns 63,932 shares in total.
Bristol-Myers Squibb Co (BMY) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.71 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 486.77% per share during the next fiscal year.
Bristol-Myers Squibb Co (NYSE: BMY) Trading Performance Indicators
Take a look at Bristol-Myers Squibb Co’s (BMY) current performance indicators. Last quarter, stock had a quick ratio of 1.15. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.16. Likewise, its price to free cash flow for the trailing twelve months is 7.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.43, a number that is poised to hit 1.51 in the next quarter and is forecasted to reach 6.07 in one year’s time.
Technical Analysis of Bristol-Myers Squibb Co (BMY)
Let’s dig in a bit further. During the last 5-days, its volume was 18.47 million. That was better than the volume of 12.23 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 16.41%. Additionally, its Average True Range was 2.17.
During the past 100 days, Bristol-Myers Squibb Co’s (BMY) raw stochastic average was set at 17.37%, which indicates a significant decrease from 19.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.60% in the past 14 days, which was higher than the 27.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $57.90, while its 200-day Moving Average is $53.53. However, in the short run, Bristol-Myers Squibb Co’s stock first resistance to watch stands at $51.78. Second resistance stands at $52.21. The third major resistance level sits at $52.83. If the price goes on to break the first support level at $50.73, it is likely to go to the next support level at $50.11. The third support level lies at $49.68 if the price breaches the second support level.
Bristol-Myers Squibb Co (NYSE: BMY) Key Stats
The company with the Market Capitalisation of 104.46 billion has total of 2,034,763K Shares Outstanding. Its annual sales at the moment are 48,300 M in contrast with the sum of -8,948 M annual income. Company’s last quarter sales were recorded 12,342 M and last quarter income was 72,000 K.
